Metformin prevents the development of chronic heart failure in the SHHF rat model.
about
Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the EndotheliumCancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Effect of acute hyperglycemia on left ventricular contractile function in diabetic patients with and without heart failure: two randomized cross-over studies.Impaired response to exercise intervention in the vasculature in metabolic syndrome.New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes.Tumor mechanics and metabolic dysfunction.Obesity and Cancer: An Angiogenic and Inflammatory Link.Effects of Metformin and Exercise Training, Alone or in Combination, on Cardiac Function in Individuals with Insulin Resistance.Metformin improves the angiogenic functions of endothelial progenitor cells via activating AMPK/eNOS pathway in diabetic miceAnti-Inflammatory Effects of Metformin Irrespective of Diabetes StatusTreatment strategies for the prevention of heart failureAntineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking.Cardiac metabolism in heart failure: implications beyond ATP production.Metformin in Diabetic Patients with Heart Failure: Safe and Effective?Paradoxic effects of metformin on endothelial cells and angiogenesis.Insulin resistance and heart failure: molecular mechanismsCardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes.Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease.Disparate Effects of Stilbenoid Polyphenols on Hypertrophic Cardiomyocytes In Vitro vs. in the Spontaneously Hypertensive Heart Failure Rat.Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction.Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction.SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.METformin in DIastolic Dysfunction of MEtabolic syndrome (MET-DIME) trial: rationale and study design : MET-DIME trial.Metformin improves ovarian follicle dynamics by reducing theca cell proliferation and CYP-17 expression in an androgenized rat model.Assessment of the early stage of cardiac remodeling of spontaneously hypertensive heart failure rats using the quantitative 3-dimensional analysis provided by acipimox-enhanced FDG-PET.Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial.Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study
P2860
Q26999344-60E8B36A-AD71-4BDB-BFDE-09D2679F3E99Q30426853-792E35A3-24E1-4F8F-8B17-403336EAEE2CQ30459207-6364D4B3-EB1C-49C1-9655-B2C288554420Q34070662-661AAF86-ED30-44FF-87D5-D5B33745C0FBQ34375466-F11D73ED-74C5-4DAF-9B9E-08C156D52D0AQ34984569-3449EA77-7C1E-4AF6-91B8-C767252D5535Q35117423-F9E5AC7D-856D-405A-AF37-584E9099EEA2Q36759129-E02CDF87-2DFD-49CE-850F-44DC541E1327Q36999950-D063959B-8C1F-49C7-B019-8CD9DDB26F7DQ37018236-A7F0C6FD-1F50-4A78-8FC0-7CCE8ED5398EQ37187900-37C0630F-3483-4A09-9956-E14E385A40AEQ37297198-BDD49CEF-3322-41E9-AE6E-BFA07A121909Q37397983-47DDE665-62B4-4617-979F-0D716B0B9E58Q37495811-1FB2BF32-7048-49AE-AE8B-47BE6BA71217Q37508043-F0CEE19A-CDD3-4BAA-AB2E-3F521287A04CQ37731504-875F5CE0-4F5B-4AD4-BFEB-68F1BA421426Q38045550-F8A2EAE9-A5DF-48CC-93A8-F47D8B3DD4D2Q38129182-5ABE3788-2F69-4CF3-8EB4-DD7DBA86F995Q38374396-848B8D67-FE15-420B-9D02-95B725F327CEQ38981344-84963424-0B26-40AD-B8E2-0A90BDE97E1EQ40380730-3FBB7F23-739F-4EE7-BBDE-C171059C0815Q40842440-A0C5FB93-2FCD-47B0-BD27-872CB3A13956Q47196867-44841F7E-F058-4EE3-B8B6-3214D8307CC9Q47744644-0AFC66B2-1E98-41FA-9501-08E986BFBA1FQ48086135-6ED0FE01-2966-43A2-8CE7-953EBE450A54Q51737343-4678A64E-B3BB-4856-9CB9-E2F7A1D041C3Q53084286-E907999D-5AAC-48F3-9031-428A913A3D48Q55400264-4EBEB443-BEBA-4AC2-B6FA-7E509F1B47F3Q58723952-E9C98D52-8641-44B0-91A9-F74BEFAF611F
P2860
Metformin prevents the development of chronic heart failure in the SHHF rat model.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Metformin prevents the development of chronic heart failure in the SHHF rat model.
@en
type
label
Metformin prevents the development of chronic heart failure in the SHHF rat model.
@en
prefLabel
Metformin prevents the development of chronic heart failure in the SHHF rat model.
@en
P2093
P2860
P50
P356
P1433
P1476
Metformin prevents the development of chronic heart failure in the SHHF rat model
@en
P2093
Gianluca Aimaretti
Jörgen Isgaard
Luigi Saccà
Mariateresa Samà
Marion Walser
Salvatore Longobardi
P2860
P304
P356
10.2337/DB11-1132
P407
P577
2012-02-16T00:00:00Z